The elevated level of MEF2C, identified both in the PD group and in the neurological control group, may be a consequence of the development of general compensatory mechanisms aimed at reducing microglial activation, as well as having a positive effect on cognitive and motor functions. This evidence concerns the gene MEF2C and Parkinson disease.